Sponsored By

Lilly
Interview with the Innovators

Evolving Adjuvant Treatment Landscape for HR+/HER2- Early Breast Cancer

Interview with the Innovators, Breast Cancer, HR+/HER2− Breast Cancer
ESMO Early Breast Cancer

This first installment observes how the adjuvant treatment landscape has evolved for patients with HR+/HER2- early breast cancer, including discussion on the monarchE study.

Video Library

Featuring:

Nadia Harbeck, MD, PhD
Director, Breast Cancer
Professor, Conservative Oncology
LMU University Hospital
Munich, Germany

Interview with the Innovators Presents:
Emerging Data in Early Breast Cancer from ESMO 2023

We are pleased to announce the release of our latest Interview with the Innovators video series. This 3-part video series features expert commentary from Dr Nadia Harbeck, MD, PhD, Ludwig-Maximilians-University of Munich. In this video series, Dr Harbeck recaps data on adjuvant treatment for patients with HR+/HER2- early breast cancer, details new data on prognostic factors in breast cancer, and discusses recent trials investigating neoadjuvant immunotherapy.

Related Items

Navigating the Complex Pathways to Clinical Trial Participation
By Jennifer Flores, MS; Marcela Orozco; Kelsey Hampton, PhD
Breast Cancer
May 2026 Vol 17, No 3
Clinical trials hold the promise of groundbreaking treatments, but the pathways to participation can be daunting. Learn how navigators are empowering patients to overcome barriers, ask the right questions, and confidently explore life-changing opportunities.
Supporting Young Patients With Breast Cancer
By Zeena Nackerdien, PhD
Breast Cancer
December 2025 Vol 16, No 12
Explore the unique challenges faced by young patients with breast cancer and learn how innovative navigation programs are bridging gaps in care and empowering patients to thrive.
Improving Abemaciclib Tolerability: Insights From the TRADE Dose-Escalation Study
By Jamie Carroll, APRN, CNP, MSN
Interview with the Innovators
Video Library
In this sixth installment, Ms Carroll discusses the TRADE study with abemaciclib and emphasizes the importance of individualized patient care, clear communication about dosing goals, and teamwork among healthcare providers to implement dose escalation effectively. This strategy aims to address patient concerns about side effects while ensuring adherence to the full treatment plan.
Journal of Oncology Navigation & Survivorship

Contact Us | Editorial Board

Amplity

© Amplity, Inc. All rights reserved.

Connect with Us

 
 
JONS

Subscribe Today!

To sign up for our print publication or e-newsletter, please enter your contact information below.

I'd like to receive:

  • First Name *
    Last Name *
     
    Profession or Role
    Primary Specialty or Disease State
    Country

Back to Top

Amplity © Amplity, Inc. All rights reserved.